Sec Form 13D Filing - venBio Global Strategic Fund III L.P. filing for Elevation Oncology Inc. (ELEV) - 2024-08-08

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

Antoinette Delhonte

venBio Partners, LLC

1700 Owens Street, Suite 595, San Francisco, CA 94158

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

1	NAMES OF REPORTING PERSONS
	venBio Global Strategic Fund III, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			2,031,920
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			2,031,920
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	2,031,920
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	3.4%
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	PN

 

 

 

 

Item 1 of the Schedule 13D is hereby amended and supplemented as follows:

This Amendment No. 4 to Schedule 13D (“Amendment No. 4”) relates to the shares of Common Stock, par value $0.0001 per share (“Common Stock”), of Elevation Oncology, Inc. (the “Issuer”), whose principal executive offices are located at 101 Federal Street, Suite 1900, Boston, Massachusetts 02110. This Amendment No. 4 amends and supplements the original statement on Schedule 13D filed by the Reporting Persons and Aaron Royston with the Securities and Exchange Commission (the “SEC”) on July 9, 2021, Amendment No. 1 to the Schedule 13D filed by the Reporting Persons and Aaron Royston with the SEC on May 27, 2022, Amendment No. 2 filed by the Reporting Persons with the SEC on September 26, 2022, and Amendment No. 3 filed by the Reporting Persons with the SEC on June 15, 2023 (collectively, the “Schedule 13D”). All capitalized terms not otherwise defined herein have the meanings ascribed to such terms in the original Schedule 13D.

Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

A total of $570,111.835, excluding commissions, was paid by Fund III to buy an aggregate 376,484 shares of Common Stock on June 15, June 16, and June 20, 2023. The working capital of Fund III was the source of the funds for the shares of Common Stock acquired by Fund III.

Item 5(a)-(c) and (e) of the Schedule 13D is hereby amended and supplemented as follows:

(a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 59,106,809 shares of Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s quarterly report on Form 10-Q, filed with the SEC on August 6, 2024.

Fund III directly holds all of the shares of Common Stock reported herein. As the sole general partner of Fund III, the General Partner III may be deemed to beneficially own the shares held by Fund III and, as the sole general partner of the General Partner III, the GP Ltd. III may be deemed to beneficially own the shares held by Fund III. As directors of the GP Ltd. III, each of the Directors may be deemed to beneficially own the shares held by Fund III.

(c) Except for the transactions listed in Exhibit 99.7 to this Amendment No. 4, there have been no transactions in the shares of Common Stock by the Reporting Persons during the past sixty days.

(e) As of April 15, 2024, the Reporting Persons ceased to beneficially own more than 5% of the outstanding shares of Common Stock of the Issuer.

Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

Exhibit 99.6	Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.
Exhibit 99.7	Schedule of Transactions, in response to Item 5(c).

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

This Schedule 13D was executed by Antoinette Delhonte on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 99.6.

---